Senesco’s SNS01 is a Potent Regulator of Programmed Cell Death and Tumor Growth in Murine Models of Multiple Myeloma

BRIDGEWATER, N.J.--(BUSINESS WIRE)--

Senesco Technologies, Inc. (Senesco or the Company) (NYSE MKT: SNT), announced today that the characteristics and activity of SNS01 have been released on-line in Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy. The print version of the article is scheduled to be published during the summer. http://www.nature.com/mt/journal/vaop/ncurrent/full/mt201294a.html

SNS01 is an earlier formulation of Senescos therapeutic candidate SNS01-T, which is currently being evaluated in a Phase 1b/2a clinical study to treat patients with relapsed or refractory multiple myeloma, said Leslie J. Browne, Ph.D., President and CEO of Senesco. SNS01 helped us to establish the benefits of modulating the eIF5A pathway to selectively trigger programmed cell death in malignant B-cells and to develop a more potent and better tolerated version to take into clinical trials.

The Company recently announced the oral presentation, entitled SNS01-T, an eIF5A-Based Gene Therapy Nanoparticle Designed for the Treatment of Multiple Myeloma, has Anti-Tumoral Activity in Lymphoma, which described the effectiveness of SNS01-T in B-cell cancers. Research for both publications was performed in Senesco CSO John Thompsons research laboratory at the University of Waterloo in Ontario, Canada.

About SNS01-T

SNS01-T is a novel approach to cancer therapy that is designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma, and, mantle cell and diffuse large B-cell lymphomas. Senesco is the sponsor of a Phase 1b/2a open-label, multiple-dose, dose-escalation study which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to relapsed or refractory multiple myeloma patients. The study is actively enrolling patients at the Mayo Clinic in Rochester, MN, the University of Arkansas for Medical Sciences in Little Rock, and the Mary Babb Randolph Cancer Center in Morgantown, West Virginia. http://www.clinicaltrials.gov/ct2/show/NCT01435720?term=SNS01-T&rank=1

About Multiple Myeloma

Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies, in which abnormal cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal blood cells. Senesco was previously granted orphan drug status for SNS01-T, the Companys lead drug candidate for treatment of multiple myeloma.

About Senesco Technologies, Inc.

Senesco, a leader in eIF5A technology, is running a clinical study in multiple myeloma with its lead therapeutic candidate SNS01-T, which targets B-cell cancers by selectively inducing apoptosis by modulating eukaryotic, translation, initiation Factor 5A (eIF5A), which is believed to be an important regulator of cell growth and cell death. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications in treating certain inflammatory and ischemic diseases. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners products.

Read the original post:
Senesco’s SNS01 is a Potent Regulator of Programmed Cell Death and Tumor Growth in Murine Models of Multiple Myeloma